LANCET ONCOLOGY, cilt.19, sa.11, ss.1468-1479, 2018 (SCI-Expanded, Scopus)
Background Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.